文献速递白血病

基线FLT3-ITD突变等位基因水平对接受强化化疗联合或不联合索拉非尼治疗的急性髓系白血病患者的预后意义

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
PubMed 文献 · Am J Hematol · 2019-06-24

本研究纳入183例FLT3-ITD突变成人AML患者,一组接受IA方案诱导化疗,另一组在IA基础上加用索拉非尼。结果显示索拉非尼组CR/CRi率更高、RFS和OS更长,且高FLT3-ITD等位基因负荷的不良预后影响在索拉非尼组被消除。

要点

  • 索拉非尼联合IA方案较单用IA方案提高CR/CRi率(99% vs 85%)。
  • 索拉非尼组中位RFS为45个月,单用IA组为12个月。
  • 单用IA组中位OS为17个月,索拉非尼组未达到。

核心结论

  • 较高的FLT3-ITD等位基因负荷与IA方案化疗患者更差预后相关。
  • 在化疗基础上加用索拉非尼不仅消除了高等位基因负荷的负面预后影响,还改善了FLT3-ITD突变AML患者的结局, regardless of allele burden。

研究设计与样本

  • 回顾性识别在本机构接受治疗的FLT3-ITD突变成人AML患者。
  • 患者分为两组:一组接受含伊达比星和阿糖胞苷(IA)的诱导方案,另一组在IA方案基础上加用索拉非尼。
  • 共纳入183例患者,其中一组104例(57%),二组79例(43%)。

主要发现

  • 一组和二组的CR/CRi分别为85%和99%(P = .004)。
  • 一组和二组的中位RFS分别为12个月和45个月(P = .02)。
  • 一组的中位OS为17个月,二组未达到(P = .008)。
  • 一组中OS的最佳FLT3-ITD突变等位基因截断值为6.9%,二组无最佳截断值。
  • 多因素分析显示,较差体能状态(PS)(P = .003)、索拉非尼(P = .01)和就诊时白细胞计数(WBC)(P < .001)是OS的独立预测因素。

关键数值与推荐

  • 一组CR/CRi率为85%,二组为99%(P = .004)。
  • 一组中位RFS为12个月,二组为45个月(P = .02)。
  • 一组中位OS为17个月,二组未达到(P = .008)。
  • 一组中OS的最佳FLT3-ITD突变等位基因截断值为6.9%,二组无最佳截断值。
  • 多因素分析中,较差PS(P = .003)、索拉非尼(P = .01)和WBC(P < .001)是OS的独立预测因素。

临床怎么用

  • 对于FLT3-ITD突变AML患者,在IA方案基础上加用索拉非尼可改善CR/CRi率、RFS和OS。
  • 索拉非尼的加入可能消除高FLT3-ITD等位基因负荷的不良预后影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Internal tandem duplication (ITD) of the fms-related tyrosine kinase-3 gene (FLT3) confer a poor prognosis in adult AML. Studies have reported that a higher mutant allelic burden is associated with a worse prognosis. Adult patients with FLT3-ITD mutated AML treated at our institution were identified. Patients were assigned into 2 groups; patients who received idarubicin and cytarabine (IA, group one) containing induction, and who received sorafenib in addition to IA containing regimens at induction (group two). The optimal FLT3-ITD mutant allele cut-off was defined as the cut-off to divide the whole cohort with the highest statistical significance. A total of 183 patients including 104 (57%) in group one and 79 (43%) in group two were identified. The complete remission (CR)/CR with incomplete hematologic recovery (CRi) for group one and group two were 85% and 99%, respectively (P = .004). The median relapse free survival (RFS) for group one and two were 12 and 45 months, respectively (P = .02). The median overall survival (mOS) was 17 months in group one, and has not been reached in group two (P = .008). The optimal FLT3-ITD mutant allele cut-off for OS was 6.9% in group one, there was no optimal cut-off in group two. On multivariate analysis, poor performance status (PS) (P = .003), sorafenib (P = .01), and presenting white blood cells (WBC) (P < .001) were independent predictors of OS. Higher FLT3-ITD allele burden is associated with a worse outcome in patients treated with IA-based chemotherapy. Addition of sorafenib to chemotherapy not only nullifies the negative prognostic impact of higher allele burden, but also improves outcome of FLT3-ITD mutated AML patients regardless of the allele burden.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Yalniz F, Abou Dalle I, Kantarjian H, et al. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019. PMID: 31237017. doi:10.1002/ajh.25553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。